摘要
目的探讨孟鲁司特钠辅助治疗儿童节段性或大叶性肺炎支原体感染的临床疗效及肺功能的变化。方法将60例确诊为节段或大叶性肺炎支原体肺炎患儿随机分为治疗组和对照组各30例,两组均给予阿奇霉素进行治疗,其中治疗组在此基础上给予孟鲁司特钠咀嚼片进行治疗。观察两组患儿的临床疗效及治疗前后肺功能的变化情况。结果治疗组痊愈率明显高于对照组(x～2=4.29,P<0.05);发热消失时间、咳嗽消失时间、肺部啰音消失时间、气喘消失及住院时间均明显短于对照组(t值分别为10.21、5.27、5.19、5.53、13.81,均P<0.05);治疗组患者用力肺活量、1秒钟用力呼气容积、第1秒最大呼吸率、25%用力肺活量时呼吸气流量和50%用力肺活量时呼吸气流量的水平均明显高于对照组,差异均有统计学意义(t值分别为10.23、10.42、6.75、14.75、9.56,均P<0.05)。结论孟鲁司特钠辅助治疗儿童节段性或大叶性肺炎支原体感染可有效的缓解临床症状、缩短发热和胸部大片影消退时间,从而减少住院天数,并且不良反应少,值得临床推广应用。
Objective To investigate the clinical therapeutic effect of montelukast in the assistance treatment of segmental and lobar mycoplasma pneumoniae （ MPP） and pulmonary function change in children .Methods Totally 60 cases with segmental or lobar MMP were randomly divided into treatment group and control group with 30 cases in each group , and two groups were given azithromycin for treatment . The treatment group was additionally given montelukast sodium tablets .Clinical efficacy of two groups and pulmonary function changes before and after treatment were observed .Results Cure rate in the treatment group was significantly higher than the control group （χ^2 =4.29, P〈0.05）.The disappearance of fever , cough, pulmonary rales and asthma was earlier in the treatment group than the control group, and the length of stay was significantly shorter （t value was 10.21, 5.27, 5.19, 5.53 and 13.81, respectively, all P〈0.05）. FVC, FEV1, FE1/FVC, FEF25 and FEF50 in the treatment group were significantly higher than the control group , and the differences were significant（t value was 10.23, 10.42, 6.75, 14.75 and 9.56, respectively, all P 〈0.05）.Conclusion Montelukast in the assistance treatment of pulmonary function of segmental and lobar MMP in children could effectively relieve clinical symptoms , reduce the duration of fever and restore of lobar shadow , and thus reduce the length of stay and adverse reactions .It is worthy of clinical application .
出处
《中国妇幼健康研究》
2014年第3期434-435,442,共3页
Chinese Journal of Woman and Child Health Research
关键词
孟鲁司特钠
肺炎支原体肺炎
肺功能
气道高反应性
哮喘
montelukast
mycoplasma pneumoniae （MPP）
pulmonary function
bronchial hyperresponsiveness
asthma
